Plaque psoriasis is responsible for a substantial burden on patients, their families, and the healthcare system. To address this burden, important treatment advances continue to be made, including a better understanding of the long-term safety and efficacy of approved medications, as well as the introduction of new classes of medications. Join Steven Feldman, MD, PhD, and Abby Van Voorhees, MD, as they report on research results of these advances presented at the 2021 American Academy of Dermatology Virtual Meeting Experience. The faculty, and principal investigators of the research, also share their thoughts about the impact of the research findings on clinical practice.
1.25 AMA PRA Category 1 CreditsTM
This activity is intended for dermatologists, pediatric dermatologists, and other clinicians who manage patients with moderate-to-severe plaque psoriasis.
This educational activity is supported by an educational grant from AbbVie, Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC, and Novartis Pharmaceuticals Corp.
Steven R. Feldman, MD, PhD
Professor of Dermatology, Pathology, and Social Sciences & Health Policy
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Abby S. Van Vorhees, MD
Professor and Chair, Department of Dermatology
Eastern Virginia Medical School